Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck KGaA ‘triples profit’ in 2007

Merck KGaA ‘triples profit’ in 2007

18th February 2008

Merck KGaA has announced its financial results for 2007, with the firm reporting that structural changes undertaken during the year are expected to have a “lasting positive effect” on both its growth prospects and financial profile.

In 2007, the company purchased biopharmaceutical company Serono and sold its generics division to Mylan.

During 2007, total revenues at Merck rose 58 per cent to 7.1 billion euros (5.3 billion pounds), while profit after tax rose 251.6 per cent to 3.5 billion euros.

These figures were bolstered by an increase in total pharmaceutical revenues from 2.3 billion euros to 4.9 billion euros, with these figures not including those for Serono.

Karl-Ludwig Kley, chairman of the executive board of Merck, said: “For Merck, 2007 was a year of major accomplishments – the successful integration of Serono, the sale of generics and a capital increase, resulting in a very low net debt at year end.

“We produced the strongest financial results in Merck’s long history, allowing us to recommend an increased regular dividend of 1.20 euros and a one-time bonus dividend of 2.00 euros.”

He forecast that 2008 would bring another year of solid economic growth at Merck, despite the uncertain economic climate.

In November 2007, Merck Serono and Ecole Polytechnique Federale de Lausanne signed a research agreement in the areas of oncology, neuroscience and drug delivery.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.